Financing ·
INmune Bio prices $4.5M registered direct offering at $1.50 per share with concurrent private placement of warrants
INMBInmune Bio, Inc.
INmune Bio entered into a securities purchase agreement to issue and sell 3,000,000 shares of common stock in a registered direct offering at $1.50 per share. Concurrently, the company sold unregistered warrants to purchase up to 3,000,000 additional shares at an exercise price of $1.65 per share. The transaction is expected to generate aggregate gross proceeds of approximately $4.5 million before fees and expenses, with closing anticipated on October 29, 2026. A.G.P./Alliance Global Partners is acting as the sole placement agent. INmune Bio operates in the biotechnology industry, focusing on developing treatments for inflammation and immunology.